cilgavimab   Click here for help

GtoPdb Ligand ID: 11329

Synonyms: AZD1061 | COV2-2130 | Evusheld® (tixagevimab + cilgavimab)
Approved drug
cilgavimab is an approved drug (EMA (2022))
Compound class: Antibody
Comment: Cilgavimab is a monoclonal antibody against the surface spike protein of SARS-CoV-2 [3]. It was developed by AstraZeneca. This mAb blocks spike binding to ACE2 and prevents infection in animals. It is designed to be a long-acting agent, and in combination with tixagevimab (co-packaged combination= Evusheld®), is proposed as a therapeutic for those people who are likely to respond poorly to SARS-CoV-2 vaccines, or who cannot be vaccinated for any reason, including those who are immunocompromised [1]. Data from the Phase 3 PROVENT trial (NCT04625725) show protection from infection that lasts for at least six months. AstraZeneca have reported that Evusheld® retains neutralising activity against the BA.1 omicron (B.1.1.529) SARS-CoV-2 variant. Cilgavimab as a single agent rmore effectively neutralises the BA.2 omicron subvariant than tixagevimab in vitro [2], so the combination retains neutralising activity.
Bioactivity Comments
Binds to the trimeric S2Pecto synthetic spike protein mimic with an EC50 of 1.5 ng/ml [3].
Selectivity at other protein targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
CoV Spike glycoprotein SARS-CoV-2 Antibody Binding - - - 3